INCR vs. SLRN, VERV, LXRX, KRRO, TBPH, CTNM, ERAS, PGEN, ORGO, and VNDA
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Acelyrin (SLRN), Verve Therapeutics (VERV), Lexicon Pharmaceuticals (LXRX), Korro Bio (KRRO), Theravance Biopharma (TBPH), Contineum Therapeutics (CTNM), Erasca (ERAS), Precigen (PGEN), Organogenesis (ORGO), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.
Acelyrin currently has a consensus target price of $12.80, suggesting a potential upside of 180.70%. Given InterCure's higher probable upside, equities analysts plainly believe Acelyrin is more favorable than InterCure.
Acelyrin received 9 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 63.16% of users gave Acelyrin an outperform vote.
InterCure has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, InterCure had 1 more articles in the media than Acelyrin. MarketBeat recorded 2 mentions for InterCure and 1 mentions for Acelyrin. InterCure's average media sentiment score of 1.88 beat Acelyrin's score of 0.34 indicating that Acelyrin is being referred to more favorably in the media.
Acelyrin's return on equity of 0.00% beat InterCure's return on equity.
Summary
InterCure beats Acelyrin on 8 of the 14 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
